Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
5.68
-0.29 (-4.86%)
Oct 16, 2026, 3:56 PM EDT - Market open
Kyverna Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
149
Market Cap
351.27M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 7.03M | 1.37M | 24.20% |
| Dec 31, 2021 | 5.66M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fennec Pharmaceuticals | 59.22M |
| Editas Medicine | 47.01M |
| vTv Therapeutics | 36.84M |
| C4 Therapeutics | 35.04M |
| Scribe Therapeutics | 33.30M |
| Orchestra BioMed Holdings | 31.98M |
KYTX News
- 9 days ago - Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026 - GlobeNewsWire
- 22 days ago - Kyverna Therapeutics Transcript: Study update - Transcripts
- 22 days ago - Kyverna Therapeutics Press release: Study update - Filings
- 22 days ago - Kyverna Therapeutics Slides: Study update - Filings
- 22 days ago - Kyverna Therapeutics Slides: Investor presentation - Filings
- 22 days ago - Swarmer’s miv-cel shows positive results in stiff person syndrome and gMG - TheFly
- 22 days ago - Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis - GlobeNewsWire
- 4 weeks ago - Kyverna Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts